Research & KnowledgeEvent: September 3, 2026
Pfizer will present at the WCLC26 conference on the analysis of the phase 3 CROWN study findings using early on-treatment AI-based imaging measures and ctDNA in patients with advanced ALK-positive NSCLC.
Published
Signal category
Research & Knowledge
Quote
“I'll be presenting at #WCLC26 on our analysis from the phase 3 CROWN study”
— Chong Duan|Pfizer team
Company
- Industry
- Pharmaceutical Manufacturing
- Location
- New York, US
- Company size
- 109,247 employees
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines